Literature DB >> 20586870

Homology model of the DNA gyrase enzyme of Helicobacter pylori, a target of quinolone-based eradication therapy.

Juntaro Matsuzaki1, Hidekazu Suzuki, Hitoshi Tsugawa, Toshihiro Nishizawa, Toshifumi Hibi.   

Abstract

BACKGROUND AND AIMS: Resistance of Helicobacter pylori to the standard therapeutic antimicrobial agents has been demonstrated. Although quinolones are an alternative candidate for third-line eradication therapy, quinolone resistance of H. pylori is also increasing. Quinolone resistance of H. pylori is caused by a point mutation of the DNA gyrase subunit A (GyrA) protein, especially on amino acids 87 and 91. The aim of this study is to surmise the structure of H. pylori GryA.
METHODS: The modeling of the 3-D structure of H. pylori GyrA was performed by an automated homology modeling program: SWISS-MODEL. The position of amino acids 87 and 91 in H. pylori GyrA was plotted on the homology model. To estimate the function of quinolone resistance-determining region (QRDR), the structure of H. pylori GyrA was compared with Escherichia coli GyrA.
RESULTS: A molecular model of H. pylori GyrA could be predicted using SWISS-MODEL. The GyrA N- and C-terminal domains closely resembled those of E. coli. The position of amino acids 87 and 91 in H. pylori GyrA was part of the DNA binding region (head dimer interface) on the GyrA N-terminal domain.
CONCLUSION: Our homology model of H. pylori GryA suggests that the quinolone resistance-determining region is on the head dimer interface of the GyrA N-terminal domain.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20586870     DOI: 10.1111/j.1440-1746.2010.06245.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  6 in total

Review 1.  Helicobacter pylori Infection, Its Laboratory Diagnosis, and Antimicrobial Resistance: a Perspective of Clinical Relevance.

Authors:  Shamshul Ansari; Yoshio Yamaoka
Journal:  Clin Microbiol Rev       Date:  2022-04-11       Impact factor: 50.129

2.  Antibiotic resistance and gyrA mutation affect the efficacy of 10-day sitafloxacin-metronidazole-esomeprazole therapy for Helicobacter pylori in penicillin allergic patients.

Authors:  Hideki Mori; Hidekazu Suzuki; Juntaro Matsuzaki; Tatsuhiro Masaoka; Takanori Kanai
Journal:  United European Gastroenterol J       Date:  2017-01-19       Impact factor: 4.623

Review 3.  Mechanisms of Helicobacter pylori antibiotic resistance and molecular testing.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki
Journal:  Front Mol Biosci       Date:  2014-10-24

Review 4.  World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat.

Authors:  Hidekazu Suzuki; Hideki Mori
Journal:  J Gastroenterol       Date:  2017-11-14       Impact factor: 7.527

Review 5.  Update on quinolone-containing rescue therapies for Helicobacter pylori infection.

Authors:  Hideki Mori; Hidekazu Suzuki
Journal:  World J Gastroenterol       Date:  2020-04-21       Impact factor: 5.742

6.  Acquisition of double mutation in gyrA caused high resistance to sitafloxacin in Helicobacter pylori after unsuccessful eradication with sitafloxacin-containing regimens.

Authors:  Hideki Mori; Hidekazu Suzuki; Juntaro Matsuzaki; Tatsuhiro Masaoka; Takanori Kanai
Journal:  United European Gastroenterol J       Date:  2017-10-08       Impact factor: 4.623

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.